AI models show moderate-to-good discrimination for ICI response and OS prognosis in BLCA, but evidence is constrained by reliance on a single trial cohort (IMvigor210) and training cohort (TCGA-BLCA), with internal and external OS validation each corroborated by only one study, limiting generalisability.
R. Das, B. Gonsalves, V. Ravindran et al.· The Oncologist· 0 citations
Dacarbazine-based chemotherapy retains modest activity in selected patients with advanced melanoma in the immunotherapy-refractory setting, and further multicenter studies are required to define predictive biomarkers and optimize patient selection.
Maleeha Anwar, G. Meléndez-Torres, R. Frazer· Anticancer Research· 0 citations
An ethnicity-based benchmarking analysis of therapeutic outcomes across standard-of-care ICI combination regimens demonstrates consistent clinical efficacy across Asian and Caucasian populations, with no statistically significant or clinically meaningful divergence in ORR or PFS.
D. Khanna, T. Dey, E. Blanchard-Cavagis et al.· The Oncologist· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.